(This content is being used for illustrative purposes only; any person depicted in the content is a model)
The opioid crisis has affected every community in America. Opioids affect rural working class people, those in the inner city and suburbs, or even the wealthy and well-to-do professionals. While drug abuse in business has been highlighted in blockbuster films like the Wolf of Wall Street, the current reality is not far from it. According to addiction experts, substance use disorder is making a sobering impact on the financial industry.
This comes from not just an upscale partying lifestyle, but also from drugs used to manage performance and stress, along with physical pain. According to addiction experts, the financial industry itself is actively turning a blind eye to the issues concerning opioid abuse on Wall Street because money is still the priority, and stigma still gets in the way.
Opioids on Wall Street: White-Collar Confessions
As it stands there is no comprehensive research that takes a detailed look at opioid abuse in Wall Street among finance professionals. So we can’t exactly show the numbers to prove it’s prevalence. However, what we see consistently is a dramatic increase in addiction and overdose rates all over the nation in recent years.
Luckily, professionals from this demographic are beginning to speak out in hopes of progressive change.
One such individual is Trey Laird, a former Wall Street trader, who recently spoke to CNBC about his six-year opioid addiction. During the conversation Laird reiterates the critical understanding that substance use disorder can reach anyone, saying:
“Addiction pervades every single socioeconomic demographic that there is. Every industry, every race, men, women. It doesn’t care who you are,”
After getting clean himself, Laird went on to open a sober living community and says he hopes to specifically serve the Wall Street and white collar demographic.
According to Laird, there has been more talk about opioid addiction among people in higher socioeconomic brackets, but there is still much work that needs to be done. He acknowledges that increasing awareness is doing a great deal, but that the problem is also at an increase. Wall Street may finally be talking about it, but how many professionals will get the help they truly need?
Opioids on Wall Street: Stocks and Stigma
One of the biggest obstacles facing white-collar workers like those in Wall Street is the engrained stigma still attached to addiction. Even with all the shifts in our culture toward a better understanding of substance use and the compassion for those struggling, professionals still have this seemingly unbearable hurdle in front of them.
Truthfully, stigma is something that prevents most people from getting help. Professionals will often be too afraid of losing their jobs to admit they need help. Many in the world of Wall Street and finance may have no information on how to seek out treatment while adhering to their professional boards’ guidelines and business practices.
With white-collar workers, this may be an especially difficult thing because the idea of addiction is so often attached to stereotypes of the unemployable, the homeless, the unreliable and unstable that their high-earning careers might minimize the impact drugs have on their lives. Wall Street stockbrokers and traders might not see themselves as having a problem as long as they can function, which brings in the idea of the “functioning addict.”
Opioids on Wall Street: Function Addiction is Still Addiction
Many white-collar workers who struggle with drugs or alcohol may consider themselves a “functioning addict”, meaning they are less likely see their actions as a problem because they are able to maintain their professional or even personal lives. To make matters worse, frequently the people around someone who is professionally successful will not believe the addiction is real. They may admit that you’ve been careless or destructive in some respects, but will ultimately minimize it due to your financial stability.
As long as you’re making money and paying the bills how could you possibly be “that bad?”
Well, because “functioning addiction” is still an addiction.
Addiction isn’t about whether or not you are able to hold down a steady income. It does not depend on whether or not other people recognize that you have a problem or your competence with your profession. While addiction can and will have an impact on these things, it isn’t always as black and white as most people like to pretend.
Notice how earlier we said you may “maintain” other areas of your life? Well, we mean to say that you can get by for a while, but eventually, the effects of addiction will catch up with you. It could be in the form of serious health consequences or other devastating circumstances. It could take days, months or even years, but it will leave a mark.
Sadly, “functioning addicts” are also far less likely to get the help they desperately need.
Opioids on Wall Street: It Could Be You
While you might be able to keep your addiction secret, in the beginning, things will eventually get worse. Eventually, your addiction will become unmanageable.
If you think you might fit the “functioning addiction” criteria, look at the following questions and answer them honestly.
- Do you often think about using drugs or drinking?
- Do you find it hard to stop after you start drinking or using?
- Are you scheduling your time around drinking or using drugs?
- Have you tried to stop before, but found that you were unable to?
- Do you drink or use drugs first thing in the morning?
- Are you drinking or using drugs at work?
- Do you hide your drug use or drinking?
- Have you done something risky, like driven drunk?
- Do you worry about your drug use or drinking?
If you find you are answering “yes” more than “no” then you should seriously consider speaking with a medical or addiction professional about your drug use or drinking.
The opioid crisis is nothing to be ignored. Despite all that we think we have learned about addiction too many professionals don’t get the help they need. No one is exempt from the destruction of addiction. Opioids don’t care what street you work on, Wall Street or not, they can ruin your life all the same. If you or someone you love is struggling, please call toll-free now. We want to help.
CALL NOW 1-888-922-5398
In December of 2016, the Palm Partners Recovery Center blog covered a story about how federal prosecutors were bringing racketeering charges against several employees of Insys Therapeutics Inc. The initial report and the controversy that followed was a profound moment considering criminal charges are rarely ever brought against pharmaceutical companies. Now it seems that even more the corporate drug dealers who helped create the opioid crisis in America are going to be finding themselves under serious scrutiny for their unethical practices.
Last week President Trump declared the opioid epidemic a public health emergency. That very same day, as if to accent the severity of the crisis and the unignorable need for change, the co-founder of Insys Therapeutics Inc. himself was arrested on fraud and racketeering charges.
Insys Therapeutics CEO Taking a Fall
John Kapoor is the former CEO of Insys Therapeutics; a founding father of one of the most prominent opioid manufacturing companies in America. As of last week, Kapoor is reported to be charged with conspiring to push the company’s signature drug for unacceptable uses through a series of bribes and kickbacks.
The drug Kapoor and his company are accused of pushing just happens to be one of the most dangerous opioids on the market, which has contributed to countless deaths across the country over the years- fentanyl.
The brand name for the product made by Insys Therapeutics Inc is Subsys. This extremely potent compound transmits the synthetic opioid fentanyl in spray form. As an opioid analgesic, people use Subsys by spraying it under the tongue for quick absorption of potent fentanyl. Technically, this drug is supposed to only be used for treating cancer patients suffering from severe pain. But according to prosecutors that is very far from the sales strategy Kapoor and his executives were using.
With recent reports showing that approximately 64,000 Americans died last year from drug overdose, and an estimated 20,100 overdose deaths linked to synthetic opioids like fentanyl, how many of those lives were impacted by the drug Insys forced onto the market with bribes?
According to the prosecution, Kapoor and several other former high-ranking executives at the company colluded to bribe doctors to write-
“- large numbers of prescriptions for the patients, most of whom were not diagnosed with cancer.”
They also allegedly-
“- conspired to mislead and defraud health insurance providers who were reluctant to approve payment for the drug when it was prescribed for non-cancer patients.”
How did they do all this?
The Insidious Work of Insys Therapeutics Inc
Back in 2016, there was the discussion of six former executives and sales-managers from Insys Therapeutics Inc. being arrested. The charges, according to the Justice Department, included:
- Conspiring to defraud health insurers
- Conspiring to bribe doctors into needlessly prescribing Subsys, the company’s fentanyl painkiller
The scam is allegedly a long list of kickback schemes, sham speaking programs, and illegitimate gifts or services.
Allegedly, doctors and nurses were paid to attend dinners at high-end restaurants. These dinners were disguised as ‘speaker programs’ that were actually described as gatherings of friends and co-workers who had no power to prescribe medications. Supposed ‘speakers’ were paid fees of up to several thousand dollars for attending these exclusive outings.
One healthcare provider reportedly received an illegal kickback to the tune of $83,000!
All of this money to bribe doctors and other healthcare professionals to prescribe Subsys, even when inappropriate. So not only were they pressuring doctors to use their product over alternatives, but also to prescribe a dangerous and potentially fatal opioid to people who didn’t even need it.
Other stories written about in Forbes include cases in:
In 2015 a nurse practitioner pleaded guilty to violating a federal anti-kickback statute by taking money from Insys to prescribe the drug to Medicare patients who did not have cancer.
A former Insys sales representative also pleaded guilty to a conspiracy to violate the anti-kickback statute by paying two doctors to prescribe the drug.
The state has filed multiple claims against Insys Therapeutics involving the pressuring prescriptions of Subsys for unapproved uses.
Doctors who have worked with the company are being investigated by states including:
U.S. attorneys in the Central District of California and the District of Massachusetts are also investigating Insys Therapeutics Inc.
Shady Gifts and Services
The buck doesn’t stop there either. It wasn’t just cash gifts for unethical practices. Insys Therapeutics wanted their partners in crime to get the full effect of their illicit activities.
The company would send its own employees to work in doctor’s offices when the physician prescribed their fentanyl fuming drug to patients. They even hired the relatives of health care providers as a favor to the family for their loyalty to Subsys.
They allegedly even set up a portion of their staff to defraud insurance companies by calling to speak with insurance representatives while posing as doctors. Some allegations state they were even misrepresenting a patients diagnosis to inflate drug sales.
A December of 2016 indictment states that Insys actively worked to defraud insurance companies by setting up the “reimbursement unit” dedicated to obtaining prior authorization from insurers and pharmacy benefit managers.
Other Insys Therapeutics Exes
Kapoor stepped down as chief executive in January. However, he is definitely not the only former Insys Therapeutics executive currently under fire. This is just the tip of a very rocky ice-berg. The indictment from 2016 included:
Michael L. Babich
Former CEO and President of the company from Scottsdale, Arizona
Former Vice President of Sales from Charlotte, North Carolina
Richard M. Simon
Former National Director of Sales from Seal Beach, California
Former Regional Sales Director from Bryant City, Michigan
Joseph A. Rowan
Former Regional Sales Director from Panama City, Florida
Michael J. Gurry
Former Vice President of Managed Markets from Scottsdale, Arizona
On January 5, 2017, all of these defendants appeared in federal court for their initial appearance and arraignment. Each has pled not guilty and been released on conditions approved by the court. A Status Conference hearing followed on September 12, 2017 that is the first of many to be held over several months. That day Massachusetts federal judge set a trial date for October 15, 2018, for the 6 executives.
For now, we have to wait and see if any of the dirty laundries from these alleged white-collar criminals come out in the wash.
Holding Big Pharma Accountable
For a long time, Big Pharma companies have been using unlawful and corrupt tactics for marketing and distribution, which many now see has brought with it some great devastation to communities across the nation. Now, during an opioid crisis that has claimed tens of thousands of lives a year, for several years, these discretions are finally catching up to those accused of corporate greed. The DEA, FBI and Justice Department, along with several state officials and district attorneys, are now aggressively pursuing charges against Big Pharma operators who have a connection to some of the most dangerous and widely abused narcotics on the market.
The acting U.S. Attorney William D. Weinreb said in a statement,
“In the midst of a nationwide opioid epidemic that has reached crisis proportions, Mr. Kapoor and his company stand accused of bribing doctors to overprescribe a potent opioid and committing fraud on insurance companies solely for profit.
“Today’s arrest and charges reflect our ongoing efforts to attack the opioid crisis from all angles,”
Kapoor was arrested in Arizona and his indictment was filed in federal court in Boston. Prosecutors say the charge of conspiracy to violate the anti-kickback law carries the possibility of up to five years in prison. However, the charges of conspiracy to commit racketeering and conspiracy to commit mail and wire fraud each carry a maximum sentence of up to 20 years in prison. Needless to say, Mr. Kapoor is in for a fight.
But many are still wondering if these executives will truly be held accountable? And truthfully, is it even enough at this point? Even if proven to be indirectly contributing to the opioid epidemic, how could anyone ever know how many lives were damaged or lost because the powerful played around with lethal prescription drugs to line their pockets?
For more important information on the dangers of prescription drugs, download our FREE E-BOOK “Big Secrets of Big Pharma: Why They Secretly Hope You Get Hooked”
DOWNLOAD FREE E-BOOK
With recent reports showing that approximately 64,000 Americans died last year from drug overdose, and an estimated 20,100 overdose deaths linked to synthetic opioids like fentanyl, how many of those lives were impacted by drugs like Subsys being forced onto the market with bribes?
More needs to be done to stop Big Pharma companies like Insys Therapeutics Inc from exploiting the system and putting the lives of millions of Americans at risk. And not just the middle-men should be accountable, but also those sitting comfortably at the top these industries. At least this is a start. But for the individual, it all starts with taking action. Getting safe and effective treatment can not just save a life, but help someone build a foundation for a better one. If you or someone you love is struggling, please call toll-free now. We want to help.
CALL NOW 1-888-922-5398